我們為患者和疾病的抗爭，開辟壹條
更有希望的前進道路
我們只有壹個目標：
將開創性的科學研究成果轉化為對抗難以治療的癌癥和神經退行性疾病的新希望。臨床試驗是這壹轉化過程中的關鍵壹步，它為患者提供了在廣泛應用之前接觸創新研究性療法的機會。
我們邀請醫生和患者探索下面列出的臨床研究。每壹項試驗都代表著壹條新的前進道路，也是邁向治愈的壹步。
如果您或您關心的人正在與癌癥作鬥爭，歡迎您了解更多信息並與我們聯系。
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Indications: advanced or metastatic non-small cell lung cancers, colorectal cancers and angiosarcoma.
A Phase 3 study of gotistobart versus docetaxel
Indications: Squamous cell carcinoma of the lung that progressed on chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.
我們衷心感謝每壹位參與這些重要試驗的患者、護理人員及家屬。我們的承諾永續，並期待未來能與醫學界分享這些寶貴的研究
成果。
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab
Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab
Indications: Platinum-resistant ovarian cancer
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan
Indications: Metastatic Castration-resistant Prostate Cancer
